Absent a federal committee’s recommendation, Duchenne muscular dystrophy advocates are trying to get states to adopt ...

Family fears losing Medicaid coverage, which they rely on for life-saving care. They face uncertainty due to new work ...

WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven ...

A recent study involving researchers from the University of Basel reveals that slowing down the intracellular transport of ...

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it ...

About Robbins LLP : A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LL have been dedicated to helping shareholders recover losses, improve corporate governance ...

Shares of Dyne Therapeutics declined after the company commenced an underwritten public offering and said it had secured up to $275 million of debt financing. The stock fell 9.8% to $8.59 on Monday.

Detailed price information for Dyne Therapeutics Inc (DYN-Q) from The Globe and Mail including charting and trades.

Stock analysts at B. Riley issued their Q2 2025 EPS estimates for Capricor Therapeutics in a research report issued on Wednesday, June 25th. B. Riley analyst M. El-Saadi anticipates that the ...

Swiss biotech Santhera has found a North American partner for its Duchenne muscular dystrophy (DMD) therapy vamorolone, ahead of an FDA decision on the drug due by 26th October.

Artificial intelligence (AI)–based electrocardiogram interpretation (AI-ECG) detected left ventricular systolic dysfunction ...

Nearly 150 new Florida laws went into effect July 1 and some of them make big changes you need to know. Here's the list.